INDEMNIFICATION AGREEMENTIndemnification Agreement • March 29th, 2022 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ________, 2021 between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and __________ (“Indemnitee”).
AMPIO PHARMACEUTICALS, INC. Common Stock ($0.0001 value per share) Sales AgreementSales Agreement • February 20th, 2020 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 6th, 2017 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 2, 2017, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
AT THE MARKET OFFERING AGREEMENT September 18, 2023At the Market Offering Agreement • September 18th, 2023 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Ampio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:
Ampio Pharmaceuticals, Inc. 8,500,000 Shares Common Stock ($0.0001 par value) plus an option to purchase from the Company up to 1,275,000 additional Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 28th, 2014 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Ampio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company collectively being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”).
AMPIO PHARMACEUTICALS, INC. Common Stock (par value $0.0001) PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • December 21st, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMPIO PHARMACEUTICALS, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • April 15th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”), as of the date first written above, as follows:
PLACEMENT AGENCY AGREEMENT June 17, 2019Placement Agency Agreement • June 17th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to act as the exclusive Placement Agent in connection with the offering (hereinafter referred to as the “Offering”) of securities of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement (defined below).
EMPLOYMENT AGREEMENTEmployment Agreement • August 29th, 2017 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This Employment Agreement (the "Agreement"), is effective as of August 16, 2017 (the “Effective Date”), and executed August 23, 2017 between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Thomas E. Chilcott, III (“Employee").
4,615,400 Shares of Common Stock AMPIO PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 13th, 2012 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 17th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 17, 2019, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate • Delaware
This Indemnification Agreement (“Agreement”) is effective as of , 2010, by and between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Ampio”), and (Name) (“Indemnitee”).
SUBSCRIPTION ESCROW AGREEMENTSubscription Escrow Agreement • December 21st, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SUBSCRIPTION ESCROW AGREEMENT, dated as of December 20, 2011 (together with Schedule A and Schedule B hereto, this “Agreement”), is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation, with principal offices located at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111 (the “Company”); AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, a New York limited liability trust company, with principal offices located at 6201 15th Avenue, Brooklyn, New York, 11219 (“Escrow Agent”); and Fordham Financial Management, Inc., a Colorado corporation, with principal offices located at 14 Wall Street, New York, New York 10005, as representative for the placement agents named in the Placement Agent Agreement (the “Placement Agent”).
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN AMPIO PHARMACEUTICALS, INC. AND DAEWOONG PHARMACEUTICALS CO., LTDLicense, Development and Commercialization Agreement • October 5th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into on August 23, 2011 (the “Effective Date”) by and between Ampio Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111 (“Ampio”), and Daewoong Pharmaceuticals Co., Ltd, having its principal place of business at 163-3 Samsungdong, Kangnam-gu, Seoul, Republic of Korea (“Daewoong”). Each of Ampio and Daewoong is sometimes referred to herein as a “Party” and collectively, as the “Parties.”
AGREEMENT AND PLAN OF MERGER BY AND AMONG AMPIO PHARMACEUTICALS, INC., AMPIO ACQUISITION, INC., AND THE DMI BIOSCIENCES CONTROL SHAREHOLDERS DATED AS OF SEPTEMBER 4, 2010Merger Agreement • January 7th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of September 4, 2010, by and among DMI BioSciences, Inc., a Colorado corporation (the “Company”), Ampio Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Ampio Acquisition, Inc., a Colorado corporation and wholly-owned subsidiary of Parent (the “Merger Subsidiary”); and the Company’s Control Shareholders (as defined below). Each of the Company, Parent and Merger Subsidiary may be referred to herein as a “Party,” and collectively as the “Parties.”
RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate • Colorado
THIS RESTRICTED STOCK AGREEMENT (this “Agreement”) is made effective as of April 17, 2009 (the “Grant Date”), by and between DMI Life Sciences, Inc., a Delaware corporation (the “Company”), and Bruce G. Miller (the “Holder”):
EMPLOYMENT AGREEMENTEmployment Agreement • December 18th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This Employment Agreement (“Agreement”) is executed on December 14, 2019 and effective as of January 10, 2020 (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and Michael Macaluso, an individual (“Executive”) (the Company and Executive each a “Party” and, collectively, the “Parties”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • February 9th, 2012 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (“Agreement”) is entered into by and between Ampio Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111, USA (“Ampio”), and Valeant International (Barbados) SRL (formerly Biovail Laboratories International SRL), a society with restricted liability established under the laws of Barbados, with its principal place of business at Welches, Christ Church, Barbados, West Indies (“VIB”), as of December 2, 2011 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2022 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This Employment Agreement (the "Agreement") is effective as of October 11, 2021 (the “Effective Date”), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA (hereinafter referred to as the "Company"), and Daniel Stokely (“Employee").
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • December 12th, 2018 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of December 11, 2018, is by and between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Holder”) of a Common Stock Purchase Warrant to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), issued by the Company, which warrant is exercisable at an exercise price (the “Exercise Price”) of $.40 per share (the “Original Warrant”).
VOTING AGREEMENTVoting Agreement • April 22nd, 2015 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS VOTING AGREEMENT (this “Agreement”), dated as of April 21, 2015, is made between Rosewind Corporation, a Colorado corporation (the “Company”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Shareholder”).
ESCROW AGREEMENTEscrow Agreement • January 7th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This Escrow Agreement dated the 30th day of September, 2010 (the “Escrow Agreement”), is entered into by and among Ampio Pharmaceuticals, Inc., a Delaware corporation (“Ampio”); James Kimmel, in his capacity as representative (the “Representative”) for the shareholders (the “Company Shareholders”) of DMI BioSciences, Inc., a Colorado corporation (the “Surviving Corporation;”Ampio, the Surviving Corporation, and the Representative are referred to in this Escrow Agreement collectively as the “Parties,” and individually, a “Party”); and Corporate Stock Transfer, Inc., a national banking association, as escrow agent (the “Escrow Agent”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 26th, 2013 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 25, 2013, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors identified on Schedule I attached hereto (collectively the “Investors”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate
This Exclusive License Agreement (“Agreement”) effective as of February 17, 2009 (the “Effective Date”) is by and between DMI BioSciences, Inc., a Colorado corporation having its principal place of business at 8400 East Crescent Parkway, Suite 600, Greenwood Village, Colorado 80111 (“DMI”), and Institute For Molecular Medicine, Inc., a non-profit corporation organized and existing under the laws of Colorado, having a place of business at 3531 South Logan Street, Suite D318, Englewood, Colorado 80110 (“IMM”).
NOTE EXTENSION AND SUBORDINATION AGREEMENTNote Extension and Subordination Agreement • February 15th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations
On November 12, 2009 and December 4, 2009, the undersigned DMI Life Sciences, Inc. , a Delaware corporation (the “Maker”), issued two promissory notes (the “Notes”) in the amount of $50,000.00 each, and promised to pay to the order of Michael Macaluso, and his successors or assigns (collectively, the “Holder”), the aggregate sum of $100,000 due under the Notes, together with interest at the rate of 6.0% (six percent) per annum until the Notes are paid in full. The Notes were originally due on April 30, 2010, and under a prior extension agreement were due on about September 1, 2010.
EMPLOYMENT AGREEMENTEmployment Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate • Colorado
This Employment Agreement (the “Agreement”), is effective as of April 17, 2009 (the “Effective Date”), between DMI LIFE SCIENCES, INC., a Delaware corporation (with its successors and assigns, referred to as the “Company”), and DAVID BAR-OR, M.D. (“Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2022 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This Employment Agreement (the "Agreement") is effective as of October 11, 2021 (the “Effective Date”), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Holli Cherevka, (“Employee").
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • February 15th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Employment Agreement (the “Amendment”), is effective as of October 1, 2010 (the “Effective Date”) between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 5445 DTC Parkway, PH 4, Greenwood Village, CO 80111, (hereinafter referred to as the “Company”), and Vaughan Clift, M.D. (“Employee”).
AMENDMENT TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • March 25th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This Amendment, dated as of March 22, 2011 (this “Amendment”), to the Agreement and Plan of Merger, dated as of September 3, 2010 (the “Merger Agreement”), by and among DMI BioSciences, Inc., a Colorado corporation (the “Company”), Ampio Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Ampio Acquisition, Inc., a Colorado corporation and wholly-owned subsidiary of Parent (the “Merger Subsidiary”); and the Company’s Control Shareholders.
AMPIO PHARMACEUTICALS, INC. STOCK OPTION CANCELLATION AND GRANT AGREEMENT FOR EXECUTIVEStock Option Cancellation and Grant Agreement • August 23rd, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK OPTION CANCELLATION AND GRANT AGREEMENT FOR EXECUTIVE (“Agreement”) is made and entered into as of the 20th day of August, 2019 (“Grant Date”) by and between Ampio Pharmaceuticals, Inc. (the “Company” or “we”) and Daniel Stokely (the “Grantee”);
STANDARD FORM OFFICE LEASE BETWEEN CSHV DENVER TECH CENTER, LLC, a Delaware limited liability company, as Landlord, AND AMPIO PHARMACEUTICALS, INC., a Delaware corporation, as Tenant Dated: May 20, 2011 For Premises Located At The Quadrant 5445 DTC...Office Lease • May 23rd, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations
This Standard Form Office Lease (this “Lease”) is made as of May 20, 2011 (the “Lease Date”), by and between CSHV DENVER TECH CENTER, LLC, a Delaware limited liability company (“Landlord”), and AMPIO PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
LOCKUP AGREEMENTLockup Agreement • April 24th, 2015 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LOCKUP AGREEMENT (this “Agreement”) is made and entered into as of April 16, 2015, by and among Rosewind Corporation, a Colorado corporation (together with any successors and assigns thereto, “Parent”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (together with any successors and assigns thereto, “Seller”). Each capitalized term used, but not otherwise defined, herein has the respective meaning ascribed to such term in the Agreement and Plan of Merger, dated as of April 16, 2015, by and among certain subsidiaries of Seller, Parent, and the other parties thereto (the “Merger Agreement”).
AMPIO PHARMACEUTICALS, INC. NOTE EXTENSION AND SUBORDINATION AGREEMENTNote Extension and Subordination Agreement • February 15th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations
On June 23, 2010, the undersigned Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), issued one promissory note (the “Note”) in the amount of $200,000.00 each, and promised to pay to the order of DMI BioSciences, Inc., and its successors or assigns (collectively, the “Holder”), the aggregate sum of $200,000 due under the Note, together with interest at the rate of 6.0% (six percent) per annum until the Note is paid in full. The Note was originally due on September 2, 2010.
AMPIO PHARMACEUTICALS, INC. EXTENTION AGREEMENT FOR NOTES PAYABLE TOTAL PRINCIPAL AMOUNT: $100,000Extension Agreement for Notes Payable • February 15th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations
On August 10, 2010, the undersigned Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), issued one promissory note (the “Note”) in the amount of $100,000.00, and promised to pay to the order of James Ludvik, and his successors or assigns (collectively, the “Holder”), the aggregate sum of $100,000.00 due under the Note, together with interest at the rate of 8.0% (eight percent) per annum until the Note is paid in full. The Note was originally due on January 31, 2011.
AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENTEmployment Agreement • July 14th, 2020 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 3 to Employment Agreement (“Amendment No. 3”) is executed and entered into on July 13, 2020, (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc. (the “Company”), and Daniel Stokely (“Executive”) (collectively, the “Parties”).
